Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2013 Mar 15

PMID 23486447

Citations 167

Authors

J K Hicks

J J Swen

C F Thorn

K Sangkuhl

E D Kharasch

V L Ellingrod

T C Skaar

D J Muller

A Gaedigk

J C Stingl

Affiliations

Soon will be listed here.

Abstract

Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.

Citing Articles

Pharmacogenetic Information on Drug Labels of the Italian Agency of Medicines (AIFA): Actionability and Comparison Across Other Regulatory Agencies.

Moschella A, Mourou S, Perfler S, Zoroddu E, Bezzini D, Soru D Clin Transl Sci. 2025; 18(2):e70138.

PMID: 39910906 PMC: 11799589. DOI: 10.1111/cts.70138.

Challenges and prospects in bridging precision medicine and artificial intelligence in genomic psychiatric treatment.

Okpete U, Byeon H World J Psychiatry. 2024; 14(8):1148-1164.

PMID: 39165556 PMC: 11331387. DOI: 10.5498/wjp.v14.i8.1148.

Biomarkers in the Diagnosis and Prediction of Medication Response in Depression and the Role of Nutraceuticals.

Beer C, Rae F, Semmler A, Voisey J Int J Mol Sci. 2024; 25(14).

PMID: 39063234 PMC: 11277518. DOI: 10.3390/ijms25147992.

Pharmacogenetics in Italy: current landscape and future prospects.

Floris M, Moschella A, Alcalay M, Montella A, Tirelli M, Fontana L Hum Genomics. 2024; 18(1):78.

PMID: 38987819 PMC: 11234611. DOI: 10.1186/s40246-024-00612-w.

and metabolism of psilocybin's active metabolite psilocin.

Thomann J, Kolaczynska K, Stoeckmann O, Rudin D, Vizeli P, Hoener M Front Pharmacol. 2024; 15:1391689.

PMID: 38741590 PMC: 11089204. DOI: 10.3389/fphar.2024.1391689.

References

Laird B, Colvin L, Fallon M . Management of cancer pain: basic principles and neuropathic cancer pain. Eur J Cancer. 2008; 44(8):1078-82. DOI: 10.1016/j.ejca.2008.03.022. View

Ketter T, Flockhart D, Post R, Denicoff K, Pazzaglia P, Marangell L . The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995; 15(6):387-98. DOI: 10.1097/00004714-199512000-00002. View

Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T . Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost. 2010; 8(8):1685-93. DOI: 10.1111/j.1538-7836.2010.03921.x. View

Potter W, Zavadil 3rd A, Kopin I, Goodwin F . Single-dose kinetics predict steady-state concentrations on imipramine and desipramine. Arch Gen Psychiatry. 1980; 37(3):314-20. DOI: 10.1001/archpsyc.1980.01780160084010. View

Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E . Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2007; 83(2):322-7. DOI: 10.1038/sj.clpt.6100291. View

Cooke R, Warsh J, Stancer H, Reed K, Persad E . The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma. Clin Pharmacol Ther. 1984; 36(3):343-9. DOI: 10.1038/clpt.1984.185. View

El-Yazigi A, Chaleby K, Gad A, Raines D . Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol. 1995; 35(1):17-21. DOI: 10.1002/j.1552-4604.1995.tb04740.x. View

Dalen P, Dahl M, Bernal Ruiz M, Nordin J, Bertilsson L . 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998; 63(4):444-52. DOI: 10.1016/S0009-9236(98)90040-6. View

Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin R, Pedersen R, Sim S . Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol. 2008; 64(12):1175-9. DOI: 10.1007/s00228-008-0529-z. View

10.

Zackrisson A, Lindblom B, Ahlner J . High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther. 2009; 88(3):354-9. DOI: 10.1038/clpt.2009.216. View

11.

Sim S, Risinger C, Dahl M, Aklillu E, Christensen M, Bertilsson L . A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79(1):103-13. DOI: 10.1016/j.clpt.2005.10.002. View

12.

Dworkin R, OConnor A, Backonja M, Farrar J, Finnerup N, Jensen T . Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007; 132(3):237-251. DOI: 10.1016/j.pain.2007.08.033. View

13.

Shimoda K, Someya T, Yokono A, Morita S, Hirokane G, Takahashi S . The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol. 2002; 22(4):371-8. DOI: 10.1097/00004714-200208000-00007. View

14.

Swen J, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A, Mulder H . Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011; 89(5):662-73. DOI: 10.1038/clpt.2011.34. View

15.

Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J . Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010; 69(3):222-30. PMC: 2829691. DOI: 10.1111/j.1365-2125.2009.03578.x. View

16.

Schenk P, van Vliet M, Mathot R, van Gelder T, Vulto A, van Fessem M . The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics J. 2009; 10(3):219-25. DOI: 10.1038/tpj.2009.50. View

17.

Halling J, Weihe P, Brosen K . The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br J Clin Pharmacol. 2007; 65(1):134-8. PMC: 2291274. DOI: 10.1111/j.1365-2125.2007.02969.x. View

18.

Thase M . Achieving remission and managing relapse in depression. J Clin Psychiatry. 2004; 64 Suppl 18:3-7. View

19.

Watson C . The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain. 2000; 16(2 Suppl):S49-55. DOI: 10.1097/00002508-200006001-00009. View

20.

Gillman P . Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007; 151(6):737-48. PMC: 2014120. DOI: 10.1038/sj.bjp.0707253. View